MarketPulse

MYQORZO

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cytokinetics Q1 2026 Results Due May 5; MYQORZO® Updates Expected

Cytokinetics will report Q1 2026 earnings May 5, discussing MYQORZO® commercialization and pipeline progress in heart failure treatments.
CYTKearnings reportheart failure
The Motley FoolThe Motley Fool··Sara Appino

Cytokinetics Executive Cashes In $929K Options as Cardiac Drug Launches

Cytokinetics insider Andrew Callos sold $929K in stock options weeks after FDA approval of heart drug myqorzo, reducing holdings by 23%.
CYTKFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Cytokinetics, Incorporated

Cytokinetics Launches MYQORZO Following FDA Approval, Guides 2026 Spending

Cytokinetics launches MYQORZO for heart disease post-FDA approval; guides $830-870M spending in 2026 with strong cash position supporting commercial expansion.
SNYBAYRYCYTKFDA approvalclinical trials